Zhejiang Hisun Pharmaceutical Reports First Three Quarters Results with Net Profit Attributable to Parent of 1.146 Billion Yuan, Up 148.56% Year-on-Year

Stock News10-28

Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) has released its financial report for the third quarter of 2026, revealing that the company achieved operating revenue of 6.521 billion yuan in the first three quarters, representing a year-on-year decline of 17.70%. The net profit attributable to shareholders of the listed company reached 1.146 billion yuan, a year-on-year increase of 148.56%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses stood at 982 million yuan, up 100.11% year-on-year. Basic earnings per share came in at 0.99 yuan.

During the first three quarters, the changes in the company's performance were primarily driven by the combined effects of improved profitability in its core business and a one-time disposal gain. Sales of innovative drugs and pet medications grew steadily, and the increase in sales volume unleashed production scale effects, leading to a continuous decline in production costs, optimized product structure, and sustained improvements in overall operational efficiency. Meanwhile, the disposal gain from the transfer of 100% equity in Provincial Pharmaceutical further boosted the net profit attributable to shareholders of the listed company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment